Major developments span abortion drug access restrictions, cancer treatment approvals, psychedelic therapy advancement, and innovative diabetes research approaches.

A U.S. appeals court temporarily blocked a federal rule allowing the abortion drug mifepristone to be dispensed through the mail, significantly curtailing access to medication abortion services.

The FDA authorized expanded access to daraxonrasib, an oral RAS(ON) inhibitor for pancreatic cancer, after the drug doubled survival rates for metastatic patients in phase 3 trials.

Vepdegestrant received FDA approval for treating ESR1-mutated breast cancer, based on phase 3 VERITAC-2 trial data showing significantly improved progression-free survival.

A new FDA regulatory pathway could accelerate approval of psychedelic therapies for treatment-resistant depression and PTSD, with psilocybin from Compass Pathways considered a leading candidate for first approval.

A Royal College of Physicians survey revealed nearly half of specialist doctors are uncertain about their role in future neighborhood NHS health teams, raising concerns about integration challenges.

Researchers proposed a new staging paradigm for advanced cutaneous squamous cell carcinoma that better distinguishes between disease progression and mortality compared to current standard classification systems.

A sirolimus-eluting balloon demonstrated comparable performance to standard care for repeat coronary in-stent restenosis at 1 year, though drug-eluting stents remain superior for single-layer disease.

Scientists created 'cyborg' islet cells by combining electronic sensors with human pancreatic cells, generating previously unavailable data on islet cell function that could advance diabetes treatment approaches.